Announced Mon, 25 May · 16:35 IST

Enclosed

Revenue Growth 20pctPat NegativeEbitda Margin CompressionExceptional ItemResults View source PDF

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-12.8%1-day move

₹1520.00

prior close

₹1500.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.1-4.0-3.7-3.9-12.8-11.2-12.8-13.0-11.7-6.6+1.2+8.2+10.2—

Up moveDown movePending

AI summary

Poly Medicure reported FY26 consolidated revenue of Rs 534.5 crore, up 21.2% from Rs 440.8 crore in FY25, driven by acquisitions of Pendracare Group and Medstream SA/Citieffe Group. However, consolidated net profit declined 5.3% to Rs 320.7 crore due to acquisition-related costs and integration expenses. Standalone revenue grew modestly by 5.2% to Rs 443 crore with net profit up 1.4% to Rs 336 crore. EPS stood at Rs 31.79 (consolidated) and Rs 33.15 (standalone). The Board recommended dividend of Rs 3.5 per share (70% payout). Auditors issued unmodified opinions. Exceptional item of Rs 680.4 lakhs relates to new labour codes impact.

Likely market impact

Revenue growth is strong at 21% but profit declined due to acquisition costs and margin pressure from integrating new businesses. The stock may see mixed reaction with investors focusing on the top-line growth offset by lower bottom-line performance.